anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The efficacy of ONZETRA Xsail for the acute treatment of migraine with or without aura was established in a multicenter, randomized, double-blind, placebo-controlled study (Study 1). 

Migraineurs enrolled in Study 1 were primarily female (84%) and Caucasian (86%), with a mean age of 42 years (range of 19 to 64). Patients were instructed to treat a moderate to severe migraine headache. Additional medications were allowed as rescue therapy beginning 2 hours after the initial treatment.

In Study 1, the proportion of patients who had headache relief defined as a reduction from moderate or severe pain to mild or no pain was assessed at 15, 30, 60, 90 minutes and 2, 24 and 48 hours after treatment with study drug. Associated symptoms of nausea, photophobia, and phonophobia were assessed as secondary endpoints. The proportion of patients who had no headache at 2 hours (120 minutes) was also assessed. 

The percentage of patients achieving headache relief 2 hours after treatment was significantly greater in the ONZETRA Xsail 22 mg group compared to those who received placebo (see Table 2 and Figure 1). For patients with migraine-associated nausea, photophobia, and phonophobia at baseline, there was a lower incidence of these symptoms at 2 hours following administration of ONZETRA Xsail compared with placebo. 

Figure 1: Percentage of Patients with Headache Relief within 2 Hours with ONZETRA Xsail 

The efficacy of ONZETRA Xsail was unaffected by presence of aura; duration of headache prior to treatment; gender, age, or weight of the subject; or concomitant use of common migraine prophylactic drugs (e.g., beta-blockers, calcium channel blockers, tricyclic antidepressants). There was insufficient data to assess the impact of race on efficacy.
The diameter of the optic nerve sheath to be measured(ONSD) with the help of ultrasonography before epidural anesthesia(pre epidural ONSD). The measurement will be measured 3 mm behind the optical disc. The measurements shall be applied in both transverse and sagittal planes for both eyes and the arithmetic mean of the four measured values.
BACKGROUND: There is currently no research on the correlation between novel inflammatory indexes systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and the risk of anemia in chronic kidney disease (CKD) population, as well as survival analysis in CKD with anemia.
METHODS: This investigation encompassed 4444 adult subjects out of the National Health and Nutrition Examination Survey (NHANES) between 2005 and 2018. The study utilized multi-variable logistic regression to assess the relationship between SII, NLR, PLR, and anemia risk occurrence in CKD population. Survival differences in CKD patients with anemia, based on varying levels of SII, NLR, and PLR were evaluated employing Kaplan-Meier and Cox proportional hazards models.
RESULTS: The adjusted logistic regression model demonstrates that SII, NLR, and PLR are associated with the risk of anemia occurrence in CKD population. Kaplan-Meier's analysis reveals significant differences in survival rates among CKD patients with anemia stratified by NLR levels. The adjusted Cox proportional hazards model shows that the higher NLR group has a 30% elevated risk of all-cause mortality contrasted with lower group (hazard ratio, HR: 1.30, confidence interval (CI) [1.01, 1.66], p value <.04). Restricted cubic spline (RCS) demonstrates no nonlinear relationship between NLR and all-cause mortality. Lastly, sub-cohort analysis indicates that in populations with diabetes, hypertension, and hyperuricemia, NLR levels have a greater impact on all-cause mortality.
CONCLUSIONS: Controlling inflammation may reduce the occurrence of anemia in CKD populations, with NLR serving to be a potential prognostic indicator for survival results within CKD patients suffering from co-morbid anemia.
OBJECTIVES: Despite continued development of targeted therapies for children with cancer, patients continue to experience an array of unwanted side effects. Children with solid tumours may experience constipation as a result of vinca alkaloid therapy, psychological stressors, periods of inactivity and opioid use. Our objective was to investigate the prevalence and treatment of constipation in hospitalised children with solid tumours treated with chemotherapy.
METHODS: We retrospectively analysed data from 48 children's hospitals in the Pediatric Health Information System, extracting patients 0-21 years of age with a solid tumour diagnosis hospitalised from October 2015 through December 2019.
RESULTS: We identified 13 375 unique patients with a solid tumour diagnosis receiving chemotherapy. Constipation was the most common gastrointestinal complaint with 8658 (64.7%; 95% Cl: 63.9% to 65.5%) having a constipation diagnosis or having received at least two laxatives during admission. Bone cancers had the highest percentage (69.9%) of patients with constipation, while Hodgkin's lymphoma had the lowest, although 52.1% of patients were affected. A total of 44% (n=35 301) of encounters received an opioid at some point during admission. Of patients receiving constipation medications, the most commonly prescribed was polyethyl glycol (n=25 175, 31.7%), followed by docusate (n=11 297, 14.2%), senna (n=10 325, 13.0%) and lactulose (n=5501, 6.9%).
CONCLUSIONS: Constipation is the most common gastrointestinal issue that children with solid tumours experience while receiving chemotherapy in the inpatient setting. Increased attention should be given to constipation prophylaxis and treatment in children with solid tumours undergoing chemotherapy, particularly those identified as high risk.
BACKGROUND: Early morphologic ultrasound, generally carried out in case of atypical first trimester serum markers (PAPP-A and/or free hCGβ <0.30 MoM), has not been re-evaluated since the possibility of performing a cell-free fetal DNA analysis in this indication. Our objective was to evaluate the usefulness of early morphological ultrasound in case of atypical profile of serum markers performed in association with Non-Invasive Prenatal Testing (NIPT).
METHODS: This was a single-center retrospective study in a tertiary maternity. Between January 2017 and December 2021, women with an atypical first trimester serum markers and low/intermediate risk for trisomy 21 (<1/50) were included. The clinical data, results of first trimester serum markers, NIPT, early morphological ultrasound and subsequent ultrasounds and other investigations (amniocentesis, pregnancy outcomes) were analyzed.
RESULTS: After exclusion of women with high-risk of trisomy 21 and lost to follow-up, 163 women were included. In 72 % of cases (117/163), women had a low risk of trisomy 21, and 39 % (59/163) had an early morphological ultrasound. Early morphological ultrasound was useful to detect severe IUGR leading to the suspicion of triploidy (3/163, 1.8 %). In all other situations, it did not allow earlier management. After analysis of the 3 triploidy cases, a collapsed profile for both serum markers was demonstrated (<0.25 MoM).
CONCLUSIONS: Systematic early morphological ultrasound in case of an atypical serum marker profile seems useless considering the performance of NIPT. An ultrasound restricted to women with both markers below 0.25 MoM would allow the early detection of triploidy.
Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
Testosterone is required for normal male health that is known to decline in aging or other conditions. Physiologically active testosterone, also known as "free" testosterone, is present as a small percentage of the total blood level, mostly bound to sex hormone binding globulin and albumin. Estimation of serum free testosterone is difficult and costly, requiring equilibrium dialysis of a serum sample. These binding proteins are not normally present in saliva. It is hypothesized that the free fraction of testosterone in blood is in equilibrium with the extravascular space, notably saliva. The sponsor proposes to test this hypothesis by sampling saliva and serum and measuring testosterone. Serum free testosterone will be measured following equilibrium dialysis. To perform this study approximately 40 eugonadal and 20 hypogonadal males will be recruited.
The invention discloses an oral mesalazine colon-specific adhesive preparation with a high drug-loading rate, which can be used for effectively treating ulcerative colitis and segmental ileitis, as well as a preparation method of the oral mesalazine colon-specific adhesive preparation. The preparation is composed of a pill-containing core and an enteric coating layer, wherein the pill-containing core consists of mesalazine, excipient, adhesive and boning agent. Compared with the other oral preparations, the oral mesalazine colon-specific adhesive pellet has the effects of improving the curative effect and lowering adverse reactions when the dosage is the same. Compared with enema and suppository, the pellet has better tolerance. The preparation method can be used for effectively controlling the temperature in the production process and avoiding an overheating phenomenon in the preparation process, and is simple in preparation process and high in drug-loading rate. Besides, the oral mesalazine colon-specific adhesive pellet is applicable to the large-dose dosing characteristic of mesalazine, thereby reducing the medicine taking inconvenience of a patient and improving the dependence of the patient.
Patients receive G3139 IV continuously on days 1-8, carboplatin IV over 30 minutes on day 6, and etoposide IV over 1 hour on days 6-8. Treatment repeats every 3 weeks for up to 6 courses in the absence of unacceptable toxicity or disease progression.
B-cells have been identified as being the crucial carriers of infectivity in the spread of transmissible spongiform encephalopathy within an infected animal. In a second step, B-cells may infect further component of the immune system, e.g. T-cells. Accordingly, the present invention provides B-cell and T-cell specific ligands for the use in diagnostics and therapeutics for transmissible spongiform encephalopathy and povides methods for the manufacture of non-infective blood products and tissue derived products. Thus, the present invention provides medicaments comprising B-cell and/or T-cell depletants, for the treatment of pathologies where the depletion of B-cells and/or T-cells, and more particularly of infective B-cells and/or T-cells is therapeutically effective. <IMAGE>
Metformin orally 500 mg twice daily for the first week, 1500 mg a day in week 2 and 2000 mg a day at week 3 and then for a period of 12 months. Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
Trauma is the sixth leading cause of death globally and the leading cause of morbidity and mortality in young patients. Blunt bowel and mesenteric injuries are rare, occuring in only 1-5% of blunt abdominal traumas, and are associated with high morbidity and mortality. In this report, we present a case of a patient with sigmoid colon perforation due to ischemia caused by mesenteric injury, who was admitted to the hospital with abdominal pain two days after a car accident. A twenty-one-year-old man was admitted to the emergency department with abdominal pain and vomiting, having been involved in a car accident as a driver two days prior. Computed tomogra-phy revealed free air in the abdomen, originating from the perforation of the sigmoid colon wall, and free fluid in the pelvic area. The patient underwent immediate laparotomy. Exploration revealed a rupture in the sigmoid mesocolon, causing ischemia and perforation. Additionally, there was a rupture in the mesentery of the terminal ileum close to the ileocecal valve, but without ischemia. Partial sig-moid colon and ileal resections were performed, followed by colocolic anastomosis and double-barrel ileostomy. He was discharged in good health after a 20-day hospital stay. Thorough clinical examination and radiological evaluation can aid in detecting visceral injuries in trauma patients. Early recognition and repair of intestinal damage can prevent severe complications.
The appetite stimulant effect of dronabinol capsules in the treatment of AIDS-related anorexia associated with weight loss was studied in a randomized, double-blind, placebo-controlled study involving 139 patients. The initial dosage of dronabinol capsules in all patients was 5 mg/day, administered in doses of 2.5 mg one hour before lunch and one hour before dinner. In pilot studies, early morning administration of dronabinol capsules appeared to have been associated with an increased frequency of adverse experiences, as compared to dosing later in the day. The effect of dronabinol capsules on appetite, weight, mood, and nausea was measured at scheduled intervals during the six-week treatment period. Side effects (feeling high, dizziness, confusion, somnolence) occurred in 13 of 72 patients (18%) at this dosage level and the dosage was reduced to 2.5 mg/day, administered as a single dose at supper or bedtime. 

Of the 112 patients that completed at least 2 visits in the randomized, double-blind, placebo-controlled study, 99 patients had appetite data at 4-weeks (50 received dronabinol capsules and 49 received placebo) and 91 patients had appetite data at 6-weeks (46 received dronabinol capsules and 45 received placebo). A statistically significant difference between dronabinol capsules and placebo was seen in appetite as measured by the visual analog scale at weeks 4 and 6 (see figure). Trends toward improved body weight and mood, and decreases in nausea were also seen. 

After completing the 6-week study, patients were allowed to continue treatment with dronabinol capsules in an open-label study, in which there was a sustained improvement in appetite.
PROBLEM TO BE SOLVED: To obtain a new skin cosmetic containing an extract of a specific vegetable belonging to the family Leguminosae and having excellent skin- beautifying effect to improve the dry feeling, poor luster, crease, chapped skin, etc. SOLUTION: This skin cosmetic contains an extract of Bauhinia variegata (alias Yoteiko) which is a small tall tree belonging to the genus Bauhinia, family Leguminosae native to Southeast Asia. The extraction solvent is a water-soluble organic solvent such as methanol, 1,3-butylene glycol or acetone or a hydrated water-soluble organic solvent. The amount of the extract of Bauhinia variegata is preferably 0.001-10wt.%, especially 0.01-5wt.% based on the total skin cosmetic. The skin cosmetic is e.g. beauty wash, milky lotion, cream, pack, foundation or lipstick.
Students in the traditional education group were given training by the researchers with a powerpoint presentation. Students are divided into 5 groups of 8 people. Training was given in 3 sessions for each group, for a total of 15 sessions. The training duration was 45 minutes for each session (one lesson hour).During the training, a projector, training slides and training videos on seizure types were used. Direct explanation and question-answer techniques were used in the training.
PROBLEM TO BE SOLVED: To obtain the subject composition which has excellent hydroxyapatite crystal formation suppressive activity and is high in dental calculus preventive effect and excellent in using feel and safety by formulating a polycarboxylic acid derived from polysaccharides containing glucose anhydride as the constitution unit. SOLUTION: This composition contains a polycarboxylic acid, which is obtained by oxidizing polysaccharides (e.g. starch and the like) containing glucose anhydride as the constitution unit with an oxidizing agent (e.g. bleaching powder and the like) in the presence of a transition metal catalyst (e.g. ruthenium catalyst and the like) and possesses a weight-average molecular weight of preferably 1,000-100,000, in an amount of 0.01-10 wt.% based on the whole composition. Further, by using a divalent metal ion (e.g. magnesium ion and the like) in addition to the above polycarboxylic acid in amounts of 0.0001-1 wt.% based on the whole composition and 0.001-2 times weight based on the polycarboxylic acid, the hydroxyapatite crystal formation suppressive activity can further be improved.
The present invention is in the field of cell therapy, in particular adoptive T cell or NK cell therapy. Human immunophilin-knockout cells (T cells or NK cells) are provided, wherein the immunophilin is FKBP12 or cyclophilin a, or a population of cells of the cells. The cells are resistant to the immunosuppressant tacrolimus and/or cyclosporine a. Can be obtained by CRISPR/Cas, such as CRISPR/Cas9 mediated immunophilin knockout or derivatization techniques. The cell may be, for example, a virus-specific (e.g., specific for any of CMV, EBV, BKV, HPV, ADV, influenza or SARS-CoV-2 antigen). It may also be a regulatory T cell. The invention also provides methods of making the inventive human immunophilin knockout T cells or NK cells, pharmaceutical compositions or kits comprising the cells, for treating or preventing viral or other pathogen infection or for treating cancer or for balancing unwanted immune responses (e.g., selected from the group consisting of autoimmune, allergic, transplant, and bystander activation). Methods of treatment are also disclosed.
SULCONAZOLE NITRATE cream 1.0% is a broad-spectrum antifungal agent intended for topical application. Sulconazole nitrate, USP, the active ingredient in SULCONAZOLE NITRATE cream, is an imidazole derivative with in vitro antifungal and antiyeast activity. Its chemical name is (±)-1-[2,4-Dichloro-β-[(p-chlorobenzyl)thio] phenethyl]imidazole mononitrate and it has the following chemical structure: 

Sulconazole nitrate, USP is a white to off-white crystalline powder with a molecular weight of 460.77. It is freely soluble in pyridine; slightly soluble in ethanol, acetone, and chloroform; and very slightly soluble in water. It has a melting point of about 130°C. 

SULCONAZOLE NITRATE cream contains sulconazole nitrate, USP 10 mg/g in an emollient cream base consisting of propylene glycol, stearyl alcohol, isopropyl myristate, cetyl alcohol, polysorbate 60, sorbitan monostearate, glyceryl stearate (and) PEG-100 stearate, ascorbyl palmitate, and purified water, with sodium hydroxide and/or nitric acid added to adjust the pH.
The invention relates to a pharmaceutical composition for treating diabetic cardiomyopathy. The composition consists of morroniside and dioscin according to a weight ratio of (1:1)-(5:1), preferably an optimal ratio of 2:1. The morroniside is separated from dogwood or honeysuckle stem, and the dioscin can be separated from Chinese yam. According to PHLC detection, the purity of the two components is more than or equal to 98 percent. The pharmacological testing shows that the pharmaceutical composition disclosed by the invention has the advantages that the curative effect is obviously improved in the aspect of treating the diabetic cardiomyopathy compared with single morroniside or single dioscin, and obvious difference is produced. The pharmaceutical composition disclosed by the invention can be applied to various preparations for treating the diabetic cardiomyopathy.
An epidural steroid injection (ESI) is a minimally invasive, image guided procedure for the treatment of back pain. Pain originating in the lumbar spine is the most common referral for ESI but the entire spine may be targeted. ESI can provide temporary but meaningful relief for patients who may have failed conservative management with oral analgesics and physical therapy. ESI may provide analgesia and anti-inflammatory effects that allow more conservative measures like physical therapy to become more effective. ESI also serves as a bridge between conservative and surgical management, intervention for postsurgical pain, or an alternative for nonsurgical candidates. This article reviews the technique for performing ESI in the cervical, thoracic, and lumbosacral spine.
In controlled clinical trials, 323 (22.5%) hypertensive patients treated with amlodipine and valsartan were ≥ 65 years and 79 (5.5%) were ≥ 75 years. No overall differences in the efficacy or safety of amlodipine and valsartan was observed in this patient population, but greater sensitivity of some older individuals cannot be ruled out. 

Amlodipine: The recommended starting dose of amlodipine 2.5 mg is not an available strength with amlodipine and valsartan.

Clinical studies of amlodipine besylate tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. Elderly patients have decreased clearance of amlodipine with a resulting increase of area under the curve (AUC) of approximately 40% to 60%. 

Valsartan: In the controlled clinical trials of valsartan, 1214 (36.2%) of hypertensive patients treated with valsartan were ≥ 65 years and 265 (7.9%) were ≥ 75 years. No overall difference in the efficacy or safety of valsartan was observed in this patient population, but greater sensitivity of some older individuals cannot be ruled out.